Stelara has been very successful in clearing up the psoriasis in patients but not very good in controlling the pain associated with psoriatic arthritis.
It's very much in the air if this drug will work.
Cosentyx on the other hand has been an allstar for AS in the studies. But like any new drug there is an understandable pause whether you would consider it or not. The way the studies are set up they get the "best" patients to produce the best data.
Not surprising on the PSA and AS crossover drugs finnari. For example the IL 6 drugs are working well for PSA but not for AS. The genetic targets seem to be different for those two.
In small Trials Stelara is performing very very well in AS patients with up to 35% of patients being put into remission by stelara and a response rate of over 65% with a ASA40 level. I don't think it is up in the air if it will work at all but rather that it does work and work well in AS.
Given the new data on the genes involved in AS both the IL 17 and the IL 23 drugs should work very well
Stelara study 
